(VIANEWS) – UP Fintech Holding Limited (TIGR), Eagle Point Credit Company (ECC), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. UP Fintech Holding Limited (TIGR)
357.3% sales growth and 5.49% return on equity
UP Fintech Holding Limited provides online brokerage services focusing on Chinese investors. The company has developed a brokerage platform, which allows investor to trade stocks, options, warrants, and other financial instruments that can be accessed through its APP and website. It offers brokerage and value-added services, including investor education, community engagement, and IR platform; and account management services. The company also provides trade execution, margin financing, and securities lending services; asset management and wealth management; ESOP management; fund license application, product design, asset custody, transaction execution, and funding allocation; fund structuring and management; and IPO underwriting services. In addition, it offers market information, community engagement, investor education, and simulated trading services. UP Fintech Holding Limited was founded in 2014 and is based in Beijing, China.
Earnings Per Share
As for profitability, UP Fintech Holding Limited has a trailing twelve months EPS of $0.1.
PE Ratio
UP Fintech Holding Limited has a trailing twelve months price to earnings ratio of 82.8. Meaning, the purchaser of the share is investing $82.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.49%.
Moving Average
UP Fintech Holding Limited’s worth is way above its 50-day moving average of $4.50 and way higher than its 200-day moving average of $4.14.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.8%, now sitting on 250.01M for the twelve trailing months.
Sales Growth
UP Fintech Holding Limited’s sales growth for the next quarter is 357.3%.
2. Eagle Point Credit Company (ECC)
24.8% sales growth and 16.45% return on equity
Eagle Point Credit Company Inc. is a closed ended fund launched and managed by Eagle Point Credit Management LLC. It invests in fixed income markets of the United States. The fund invests equity and junior debt tranches of collateralized loan obligations consisting primarily of below investment grade U.S. senior secured loans. Eagle Point Credit Company Inc. was formed on March 24, 2014 and is domiciled in the United States.
Earnings Per Share
As for profitability, Eagle Point Credit Company has a trailing twelve months EPS of $1.71.
PE Ratio
Eagle Point Credit Company has a trailing twelve months price to earnings ratio of 5.68. Meaning, the purchaser of the share is investing $5.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.45%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 15.2% and a negative 5.7%, respectively.
3. Neurocrine Biosciences (NBIX)
20.8% sales growth and 15.55% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $3.32.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 33.78. Meaning, the purchaser of the share is investing $33.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.55%.
Sales Growth
Neurocrine Biosciences’s sales growth for the next quarter is 20.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 2.12B for the twelve trailing months.
Volume
Today’s last reported volume for Neurocrine Biosciences is 548899 which is 40.47% below its average volume of 922148.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 89% and 9%, respectively.
4. Celestica (CLS)
14.2% sales growth and 20.99% return on equity
Celestica Inc. provides hardware platform and supply chain solutions in North America, Europe, and Asia. It operates through two segments, Advanced Technology Solutions, and Connectivity & Cloud Solutions. The company offers a range of product manufacturing and related supply chain services, including design and development, engineering, supply chain management, new product introduction, component sourcing, electronics manufacturing and assembly, testing, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics, asset management, product licensing, and after-market repair and return services. It also provides enterprise-level data communications and information processing infrastructure products, such as routers, switches, data center interconnects, servers, and storage-related products; capacitors, microprocessors, resistors, and memory modules; and power inverters, energy storage products, smart meters, and other electronic componentry. The company serves aerospace and defense, industrial, energy, healthtech, capital equipment, original equipment manufacturers (OEMs), cloud-based, and other service providers, including hyperscalers, and other companies in a range of industries. Celestica Inc. was incorporated in 1994 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Celestica has a trailing twelve months EPS of $3.06.
PE Ratio
Celestica has a trailing twelve months price to earnings ratio of 16.69. Meaning, the purchaser of the share is investing $16.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.99%.
Sales Growth
Celestica’s sales growth is 18.1% for the present quarter and 14.2% for the next.
5. CONMED Corporation (CNMD)
5.6% sales growth and 11.86% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $3.14.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 21.21. Meaning, the purchaser of the share is investing $21.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.
